AbbVie Inc. (ABBV) Earnings Call Transcripts

AbbVie Inc.'s Latest Earnings Call - Q2 FY2026

In the second quarter of fiscal year 2026, AbbVie Inc. reported total net revenues of nearly $17 billion, exceeding expectations by $300 million and reflecting a robust year-over-year growth of 10.2%. Adjusted earnings per share (EPS) came in at $3.65, surpassing the guidance midpoint by $0.06. Management raised full-year revenue guidance by $300 million, now forecasting approximately $67.6 billion, driven by strong sales from Skyrizi, Rinvoq, and the neuroscience portfolio. The company also announced the planned acquisition of Apogee Therapeutics, which is expected to enhance its immunology portfolio significantly.

Reported metrics

Guidance from management

Management raised full-year revenue guidance to approximately $67.6 billion and adjusted EPS guidance to between $13.87 and $14.07, reflecting strong second-quarter performance and anticipated dilution from the Apogee acquisition.

What management said

Thanks, Scott. We will now open the call for questions. In the interest of hearing from as many analysts as possible over the remainder of the call, we ask that you please limit your questions to 1 or 2. Operator, we'll take the first question. .

And Chris, this is Rob. I'll just add. I mean, we always view this as a market expanding competitive launch, and that's exactly how we're seeing it. Obviously, we're still investing. I mean, I think you've seen some disease awareness investments that we've made. And so we are seeing very nice momentum continue. And I think Jeff's point that is highlighting here that we're actually seeing an acceleration of NBRx growt...

What analysts pressed on

Analysts expressed concerns about the impact of increasing biosimilar competition on Humira's sales and how this might affect overall revenue growth. Additionally, there were questions regarding the competitive landscape for Skyrizi and Rinvoq amidst new entrants in the immunology market.

Main topics on the call

• Revenue Growth Acceleration — AbbVie achieved total net revenues of nearly $17 billion, reflecting a year-over-year growth of 10.2%. Management stated, "AbbVie delivered another excellent quarter with results once again exceeding our expectations."
• Strong Performance of Key Products — Skyrizi and Rinvoq both delivered over 20% growth, with Skyrizi sales reaching $5.5 billion, up 24% on an operational basis. Management noted, "The performance of Skyrizi, Rinvoq and our neuroscience portfolio continues ...
• Acquisition of Apogee Therapeutics — AbbVie announced the planned acquisition of Apogee Therapeutics, which will enhance its immunology portfolio with multiple differentiated assets. This acquisition is seen as a strategic move to support AbbVie's long-term...
• Pipeline Advancements — AbbVie reported significant progress in its R&D pipeline, including the U.S. approval of Decupaz for a rare blood cancer and European approvals for Qulipta for migraines. Management highlighted, "We continue to make exce...

Read the full AbbVie Inc. transcript (Q2 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 86 AbbVie Inc. earnings call transcripts on record, spanning January 15, 2020 to July 31, 2026. Based on this history, AbbVie Inc. reports quarterly. The most recent call on file is dated July 31, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

ABBV

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

86

First call

January 15, 2020

Most recent

July 31, 2026

Reporting cadence

quarterly